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IMPORTANCE A recently published study of national data byMcGrath et al in 2014 showed
increased risk of schizophrenia (SCZ) in offspring associated with both early and delayed
parental age, consistent with a U-shaped relationship. However, it remains unclear if the risk
to the child is due to psychosocial factors associated with parental age or if those at higher
risk for SCZ tend to have children at an earlier or later age.
OBJECTIVE To determine if there is a genetic association between SCZ and age at first birth
(AFB) using genetically informative but independently ascertained data sets.
DESIGN, SETTING, AND PARTICIPANTS This investigation usedmultiple independent
genome-wide association study data sets. The SCZ sample comprised 18 957 SCZ cases and
22 673 controls in a genome-wide association study from the second phase of the Psychiatric
Genomics Consortium, and the AFB sample comprised 12 247 genotyped womenmeasured
for AFB from the following 4 community cohorts: Estonia (Estonian Genome Center Biobank,
University of Tartu), the Netherlands (LifeLines Cohort Study), Sweden (Swedish Twin
Registry), and the United Kingdom (TwinsUK). Schizophrenia genetic risk for each woman in
the AFB community sample was estimated using genetic effects inferred from the SCZ
genome-wide association study.
MAIN OUTCOMES ANDMEASURES We tested if SCZ genetic risk was a significant predictor of
response variables based on published polynomial functions that described the relationship
betweenmaternal age and SCZ risk in offspring in Denmark. We substituted AFB for maternal
age in these functions, one of which was corrected for the age of the father, and found that
the fit was superior for themodel without adjustment for the father’s age.
RESULTS We observed a U-shaped relationship between SCZ risk and AFB in the community
cohorts, consistent with the previously reported relationship between SCZ risk in offspring
andmaternal age when not adjusted for the age of the father. We confirmed that SCZ risk
profile scores significantly predicted the response variables (coefficient of determination
R2 = 1.1E-03, P = 4.1E-04), reflecting the published relationship betweenmaternal age and
SCZ risk in offspring byMcGrath et al in 2014.
CONCLUSIONS AND RELEVANCE This study provides evidence for a significant overlap
between genetic factors associated with risk of SCZ and genetic factors associated with AFB.
It has been reported that SCZ risk associated with increasedmaternal age is explained by the
age of the father and that de novomutations that occur more frequently in the germline of
older men are the underlying causal mechanism. This explanationmay need to be revised if,
as suggested herein and if replicated in future studies, there is also increased genetic risk of
SCZ in older mothers.
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P arental age is a risk factor for a range of adversementalhealth outcomes in children, including common psy-chiatric disorders, such as schizophrenia (SCZ).1-3 Ad-
vancedpaternal agehas received themost attention,with risk
to children widely assumed to be explained by de novo mu-
tations that occur more frequently in the germline of older
men,4-6 althoughother studies7,8 question the denovomuta-
tionhypothesis.There isalsoemergingevidencetosuggest that
children of both younger9 and older10 mothers are at in-
creased risk of psychosis.
One recent major study is by McGrath et al,11 who per-
formed a comprehensive analysis using family data extracted
fromtheDanishPsychiatric Central Register and reported aU-
shaped relationship between maternal age and risk of SCZ in
offspring. They showed that there was higher risk in children
of younger and older mothers compared with those of inter-
mediateage (25-29years). In their secondaryanalyses thatwere
adjusted for the ageof the father,which tends tobehighly cor-
related with mother’s age, increased risk of SCZ was associ-
atedwith youngermothers (<25 years) but not oldermothers.
Conversely, children of older fathers (>29 years) were at in-
creased risk, evenafter correcting for theageof themother,but
children of younger fathers were not. These epidemiological
findings for theassociationofmaternal ageandriskofSCZcan-
notdissect cause fromconsequence.That is, it is unclear if risk
to offspring is due to psychosocial, lifestyle, or biological ag-
ing factors associatedwithmaternal age or ifwomenat higher
risk for SCZ tend, on average, to have their first child at an ear-
lier or later age. Herein, our analyses use a novel design to ex-
plore the relationship between age at motherhood and SCZ.
Recentlydevelopedwhole-genomeanalysismethodspro-
vide anopportunity to investigate this question in anovelway
that is independent of potential confounding factors. Ge-
nomic relationships and risk profile scores on unrelated indi-
viduals derived from genome-wide single-nucleotide poly-
morphism (SNP)data canbeused todissect the sharedgenetic
architecture of complex traits.12 For instance, independently
collected unrelated individuals can be linked through ge-
nomic information, correlating their genotype sharing with
similarities in their phenotypes. Because the individualswho
are compared are not related in the conventional sense, any
covariance between their shared genome and their pheno-
type is most likely genetic and likely free of confounding en-
vironmental effects. This novel design enables the use of in-
dependent genome-wide association study (GWAS) data sets
toquantify theextentof genetic overlapacross complex traits.
Herein, we investigated the genetic relationship between
SCZ and age at first birth (AFB) inwomen usingmultiple inde-
pendentGWASdatasets.Specifically,weusedgeneticriskalleles
and their effect sizes estimated from SCZ GWAS data to create
a genetic SCZ riskprofile score for eachwoman in theAFBdata
set.TheAFBdata set comprises community samplesofwomen
(ie,not ascertained forpsychiatricdisorders)whohad their age
atbirthof their first child recorded.WhilebothSCZandAFBare
heritable traits,13-15 here the genetic contribution underpin-
ning the trait age at first motherhood is not dependent on the
ageofherpartner.Wetested if the relationshipbetweenawom-
an’s AFB and her SCZ risk profile score matched that reported
by McGrath et al11 between the age of mothers and the inci-
dence rate ratio (IRR) for SCZ in their children.
Methods
Each study obtained ethical board approval and written
informed consent from all participants (eAppendix 1 in the
Supplement). The SCZ sample comprised 18 957 SCZ cases
and 22673 controls in a GWAS from the second phase of the
Psychiatric Genomics Consortium (PGC2-SCZ),15 and the AFB
sample comprised 12 247 genotyped women measured for
AFB from the following 4 community cohorts: Estonia (Esto-
nian Genome Center Biobank, University of Tartu), the Neth-
erlands (LifeLines Cohort Study), Sweden (Swedish Twin Reg-
istry), and the United Kingdom (TwinsUK) (eAppendix 1 in the
Supplement contains full details). These community cohorts
measured for AFBwere not enriched for psychiatric disorders.
We used genomic best linear unbiased prediction (GBLUP),
implemented in the MTG software,16 to estimate SNP effects
in our quality-controlled PGC2-SCZ data set (n = 41 630)
(eTable 1 in the Supplement lists sample details). Briefly, SNP
effects were estimated jointly within a linear mixed model
that intrinsically accounts for linkage disequilibrium between
SNPs. In estimating SNP effects, we fitted sex, cohort, and 20
ancestry principal components obtained from the sample to
control for potential confounding effects, such as population
stratification and potential batch effects. The SNP risk predic-
tors were projected into the AFB samples, resulting in a
GBLUP risk profile score for each individual. We repeated our
analyses using standard genetic risk profile scores17,18 (eAp-
pendix 2 in the Supplement), in which the SCZ risk scores in
the women measured for AFB were estimated by summing
the count of the SCZ risk alleles weighted by their effect sizes
(log[odds ratio]) estimated from our quality-controlled SCZ
GWAS data. A regression of phenotype on genetic risk profile
score tests for association between the measures. The GBLUP
risk profile score is expected to be more accurate than a stan-
dard risk profile score because the available data in the SCZ
sample are used more optimally in the GBLUP linear mixed-
model methodology. In particular, arbitrary decisions about
P value and linkage disequilibrium clumping that are inherent
in standard profile scoring are avoided.
Key Points
Question Is there a genetic association between schizophrenia
(SCZ) and age at first birth (AFB) in women?
Findings In the analyses, the SCZ genome-wide association study
(GWAS) comprised 18 957 cases and 22 673 controls, and the AFB
GWAS comprised 12 247 women. Using thesemultiple
independent GWAS data sets, we found a significant genetic
association between SCZ risk and AFB.
Meaning SCZ risk in offspring associated with early and delayed
maternal age is partly explained by the genetic association
between SCZ and AFB
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ThedistributionofAFBandyearofbirth foreachcohortare
summarizedinTable1andeFigure1andeFigure2 intheSupple-
ment. In analyses for AFB, we generated 2 response variables
usingpolynomial functionsderived fromMcGrathet al11 tode-
scribe therelationshipbetweenIRRforSCZ inoffspringandma-
ternal age (model 1 [2.7214 + 0.0018x2 − 0.1105x]) ormaternal
age adjusted for the age of the other parent and urbanization
of the place of birth (model 2 [2.5438 + 0.0012x2 − 0.0889x]).
eFigure 3 and eFigure 4 in the Supplement show how we de-
rived the polynomial functions. In generating themodel 1 and
model 2 values for each individual, AFBwasused as the xvari-
able in the equations. In analyses, we used the residuals of the
model 1 ormodel 2 values after regression on covariates, such
as age at interview, 20 ancestry principal components, and co-
hort.Wedid not include year of birth as a covariate because its
negativevaluewashighlycorrelatedwithageat interview(>0.9).
The fitted residuals were regressed against risk profile scores,
andwereport theproportionofvariance (R2) attributable to the
polygenic score.ThePvalue results fromthe testof thehypoth-
esisR2 = 0.Thepurposeof these analyseswas to test if the SCZ
polygenic risk values are a better fit to the phenotypic risk val-
uespredictedbymodel 1ormodel2.AsmallerPvalueformodel
1would implyabetter fit to theAFBdata comparedwithmodel
2, forwhich the linear and quadratic coefficientswere derived
frommodels that adjusted for the age of the partner. Analyses
were performed for the entire AFB sample and for subsets of
womenstratifiedby themeanAFB (26years) intoyoungerAFB
(<26 years) and older AFB (≥26 years).
Results
We sought to provide insight to the relationship betweenma-
ternal age and SCZ by exploring genetic overlap between SCZ
risk inwomenmeasured forAFB.Weobserved aU-shaped re-
lationship between AFB and SCZ risk profile scores derived
using GBLUP (Figure), consistent with the relationship re-
portedbyMcGrathet al11 betweenSCZrisk inoffspringandma-
ternal agenot adjusted for the father’s age. Themean riskpro-
file score from GBLUP analysis was significantly higher in
womenwith early AFB (ie, <20 years) than inwomenwith in-
termediate AFB (P = 8.8E-03 for AFB of 25 to <30 years and
P = 1.3E-02 forAFBof 30 to <35 years) (eTable 2 in the Supple-
ment). The results fromstandardprofile scorewere very simi-
lar to those from GBLUP but showed weaker signals (eFigure
5 and eFigure 6 in the Supplement).
We further investigated if SCZ genetic risk profiles signifi-
cantly predicted the model 1 or model 2 response variables,
which are the phenotypic predictors of SCZ risk derived from
the results reported by McGrath et al11 (Table 2). We initially
focusedona subsample ofwomen45years or older at recruit-
ment (n = 10836) to avoid any potential bias owing to the in-
clusion of women who were childless at recruitment but still
of childbearing age. In analyses of the full range of AFB in this
sample, the model 1 and model 2 response variables were
strongly predicted by GBLUP-derived SCZ risk profile scores
(P = 4.1E-04 andP = 5.0E-03 formodel 1 andmodel 2, respec-
tively). The smaller P value for model 1 implies a better fit to
theAFBdata comparedwithmodel 2,which is consistentwith
the suggestion that adjusting for paternal age removes a true
association betweenmaternal age and IRR for SCZ. When re-
stricting the analysis to youngermotherswhoseAFBwas less
Table 1. Sample Size and Age at First Birth Across 4 Cohorts
Cohort
Sample
Size
Age at Interview,
Mean (Range), y
Age at First Birth,
Mean (Range), y
Estonian Genome Center
Biobank, University of
Tartu
1660 67.3 (45-101) 24.8 (15-46)
LifeLines Cohort Study 5344 53.1 (27-93) 26.7 (16-43)
Swedish Twin Registry 3262 58.2 (45-86) 25.1 (14-52)
TwinsUK 1981 55.4 (25-86) 25.7 (14-44)
Figure. Mean Schizophrenia Profile Scores FromGenomic Best Linear
Unbiased Prediction (GBLUP) in Community Samples ofWomen
(No Ascertainment Based on Psychiatric Disorders) Grouped by Age
at Birth of Their First Child
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Table 2. Coefficients of Determination and PValuesa
Data Set
Response
Variable R2 P Valueb
Full range of age at first birth
(n = 10 836)
Model 1 1.1E-03 4.1E-04
Model 2 6.4E-04 5.0E-03
Age at first birth <26 y
(n = 5827)
Model 1 1.8E-03 6.2E-04
Model 2 1.9E-03 5.1E-04
Age at first birth ≥26 y
(n = 5009)
Model 1 1.0E-03 1.4E-02
Model 2 6.5E-05 2.5E-01
a In the analyses, either themodel 1 or model 2 variables were used as the
dependent variables in regression on the genomic best linear unbiased
prediction risk profile score using only women 45 years or older at
recruitment. Age at first birth was used as the x variable in this study. The
analyzedmodel 1 andmodel 2 variables were the residuals from a regression
fitting potential confounders as covariates. Including the genetic profile score
for educational attainment as a covariate had little impact on these results
(eTable 8 in the Supplement). Model 1 polynomial function is derived from the
incidence rate ratio for schizophrenia bymaternal age (x) by McGrath et al11
(2.7214 + 0.0018x2 − 0.1105x). Model 2 polynomial function is derived from
the incidence rate ratio for schizophrenia bymaternal age adjusted for the age
of the other parent and urbanization of the place of birth (x) by McGrath et al11
(2.5438 + 0.0012x2 − 0.0889x).
bP value for the null hypothesis R2 = 0.
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than themean (AFB<26years), thePvalueswereP = 6.2E-04
and P = 5.1E-04 formodel 1 andmodel 2, respectively. On the
other hand, assessing only older mothers (AFB ≥26 years),
GBLUPprofile scoreweaklypredictedmodel 1 (P = 1.4E-02)but
notmodel 2 (P = 2.5E-01).We repeated the analyses using the
total sample of 12 247 women and found almost identical re-
sults (eTable 3 in the Supplement), suggestingvery little if any
bias arising from the inclusion of an additional 1411 women
younger than 45 years at recruitment. Again, analyses based
on the profile score approach gave similar but weaker signifi-
cance than GBLUP (eTable 4 in the Supplement).
Inourprimaryanalyses,weexcludedwomenwithoutchil-
dren because the appropriate way to include such women in
our analyses is difficult to determine. DelayedAFB and child-
lessnessmighthaveacommongeneticpredispositionormight
be on distinct dimensions of liability. To explore this, we re-
peated the analyses with the inclusion of women having no
children, whose age at recruitment was 45 years or older. In
this analysis, we assigned women having no children an AFB
of 45 years, which has been reported as the end of reproduc-
tive age.19 Both response variables were predicted in analy-
ses across the full range of AFB; however, the significance of
the prediction was considerably decreased, and neither re-
sponsevariablewaspredicted in analyses ofwomenwithAFB
of 26 years or older (eTable 5 in the Supplement). These re-
sultsmust be interpretedwith cautionbecause there couldbe
many reasons why women have no children, with the most
common being infertility, which is likely to be genetically in-
dependent of AFB among those able to conceive.
In addition to analyses of the total AFB sample,we exam-
ined the relationship between SCZ risk profile scores from
GBLUPand themodel 1 andmodel 2 responsevariables ineach
cohort (eTable 6 in the Supplement), acknowledging that ow-
ing to smaller sample size the power to detect a relationship
was substantially reduced. For Estonian Genome Center Bio-
bank, University of Tartu, risk profile scores were not signifi-
cantly associatedwithAFB (see theDiscussion section).How-
ever, a significant association remained in the other cohorts
for at least 1 responsevariable. Theprediction for theLifeLines
Cohort Studywas significant formodel 1whenusing thewhole
range of AFB or AFB younger than 26 years. For the Swedish
Twin Registry, it was significant only for model 1 in analyses
of women with AFB of 26 years or older. For TwinsUK, both
responsevariableswerepredicted in analyses of the full range
of AFB and AFB younger than 26 years but not in analyses of
womenwith AFB of 26 years or older (eTable 6 in the Supple-
ment). Due to smaller sample size, the U-shaped relationship
observedbetweenSCZ risk andAFBwas less apparent in each
cohort.
We stratified the AFB sample into birth cohorts born be-
fore or after 1945, a demarcation based on the second demo-
graphic transition that is linked in the literature to postpone-
mentofAFB.20For individuals bornafter 1945, SCZ riskprofile
scores from GBLUP significantly predicted AFB for the entire
sample and the younger AFB group but not for the older AFB
group (eTable 7 in the Supplement). For individuals born be-
fore 1945, SCZ risk profile scores from GBLUP did not signifi-
cantly predict AFB.
Discussion
Maternal age is a risk factor for a number of adverse mental
health outcomes, including common psychiatric disorders,
such as SCZ.21,22 In a recent study, McGrath et al11 reported a
U-shaped relationship between maternal age and risk of SCZ
in children, although in analyses corrected for the age of the
other parent only children of younger mothers were at in-
creased risk. Their study implied that risk of SCZ in children
of older mothers was attributable to the father’s age, consis-
tent with the hypothesis of risk arising from paternal age-
related de novo mutations and the presence of a strong cor-
relationbetweenmaternal andpaternal age.However,because
a larger proportion of older men have younger partners than
is the case for olderwomen, there is a possibility that correct-
ing for the age of the spouse may remove a true effect due to
advancedmaternal age. In otherwords, thewell-knownprob-
lemof collinearity,23-25which can lead to biased estimates for
explanatory variables that are adjusted for a correlated vari-
able (eg, maternal age adjusted for paternal age), may result
in an underestimate of the risk due to older maternal age in
analyses, such as that reported by McGrath et al.11 Our study
uses a novel experimental design that is free of effects of the
partner’s age; therefore, there is no concern about such a col-
linearity problem in our analyses.
Maternal age is a proxy for factors other thanparental age,
including de novo chromosomal abnormalities, and psycho-
social factors related to socioeconomic status and educa-
tionalattainment,bothofwhichareassociatedwithriskofSCZ.
Conversely, relatives of individuals affected with SCZ tend to
have poor social interactions,26 whichmay increase the time
taken to findamateand therebydelayAFB.Schizophrenia risk
may also predispose to risk taking and impulsive behavior,
which is associated with early pregnancy and childbirth in
women.27-29 Consequently, risk of SCZ in offspringdue toma-
ternal AFB may be influenced by shared genetic factors be-
tween mothers and offspring, as has been suggested for pa-
ternal AFB.7,8
In this study,we investigatedgenetic overlapbetweenSCZ
and AFB using a novel experimental design based on ge-
nomicdata thatenablesgeneticeffects tobedisentangled from
other confounding factors. This is achieved through indepen-
dently collected SCZ andAFBdata sets that are genetically in-
formative.TheAFBdataarecollectedfromcommunitysamples
with no known enrichment for psychiatric disorders. In par-
ticular,we sought todetermine if response variables basedon
the relationships reported byMcGrath et al11 betweenmater-
nal age and SCZ risk in children (model 1 and model 2) could
bepredictedbySCZ riskprofile scores inour independentdata.
We found that SCZ risk profile scores predicted both model 1
and model 2, implying that polygenic variation for SCZ con-
tributes to the relationships reported by McGrath et al11 be-
tweenmaternal age and risk of SCZ.
Our results were stronger for the U-shaped model 1 re-
sponse variable (based on unadjusted IRR) than model 2 (in
which IRR was adjusted for paternal age and urbanization of
the place of birth), suggesting that polygenic variation
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contributes to risk of SCZ associated with both early and de-
layed maternal AFB. In analyses stratified by the mean AFB,
evidence for genetic overlap betweenSCZ andAFBwas stron-
gest in women with early AFB (<26 years). In analyses of
women with delayed AFB (≥26 years), we observed an asso-
ciationwith the SCZ risk profile score but only for themodel 1
response based on unadjusted IRR. Given that ourmethodol-
ogyexplores the relationshipbetweenAFBgenetic riskandSCZ
in a way that is independent of correlation between the ages
of the parents, our analyses suggest that risk of SCZ in chil-
dren of older mothers is not solely attributable to factors as-
sociated with advanced paternal age.
A caveat of our findings is that the genetic association be-
tween risk of SCZ and delayed AFB was only marginally sig-
nificant given thenumber of analyses performed, perhaps re-
flecting smaller sample size and correspondingly larger
standard errors for women with delayed AFB, and so require
replication ina larger sample. Provided that this finding is con-
firmed in a future study, it has important implications be-
cause it implies that risk of SCZ associatedwith increased age
in mothers is not entirely due to the father’s age.
Althoughwedemonstrate that SCZgenetic risk canbedis-
entangled frompsychosocial, lifestyle, andbiological aging fac-
tors in assessing the relationship between SCZ risk and AFB,
we cannot explicitly determinemechanism, and it is possible
that subtle correlations between genetic and nongenetic fac-
tors might influence this relationship. Several mechanisms,
such as correlation of SCZ riskwith socioeconomic status and
other environmental and biological factors, might also influ-
ence the genetic relationship between SCZ and AFB. For in-
stance, SCZ risk couldpredispose to impulsive behavior29 and
substanceuse,27whichareassociatedwithearlypregnancyand
childbirth.28On theotherhand,poor social competence inSCZ
mightdelay the time tomeet apartner orhaveoffspring, caus-
ing delayedAFB.Other plausiblemechanisms, such as low IQ
and poor educational attainment, which are strong risk fac-
tors for both SCZ30 and early pregnancy,21 need to be ex-
plored, although the inclusion of the genetic profile score for
educational attainment as a covariate had little impact on our
results (eTable 8 in the Supplement). Assessing these factors
is beyond the scope of this study. Future research that in-
cludes social science measures and information on nonge-
netic factors will facilitate a deeper understanding of causal
pathways underlying the association between SCZ and AFB.
The analyses byMcGrath et al11 explored the relationship
between parental age and a broad range of psychiatric disor-
ders. Herein,wehave only considered genetic risk for SCZ be-
cause sample size, and hence the power to estimate risk al-
lele effect sizes, is greatest. For example, 108 independent risk
loci for SCZ have been identified as being genome-wide
significant15 compared with only 3 for bipolar disorder.31 As
GWAS sample sizes for other psychiatric disorders increase,
then replication of our analyses based on these disorderswill
be possible.
Conclusions
Insummary, this studyprovidesevidence forasignificantover-
lapbetweengenetic factors associatedwith riskof SCZandge-
netic factors associatedwithAFB.Toourknowledge, this is the
first study to explore a genetic relationship between SCZ and
AFB using independent unrelated samples based on genomic
data. We conclude that women with high genetic predisposi-
tion toSCZ tend tohave their first child at anearly ageor a later
age compared with women in the general population.
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